Regeneron Pharmaceuticals

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$3,675,600
$3,028,700
$3,789,200
$3,720,700
Gross Profit
3,010,300
2,437,500
3,097,700
3,107,900
EBITDA
1,657,400
1,040,600
1,095,000
1,628,500
EBIT
1,522,300
913,700
968,600
1,506,800
Net Income
1,391,600
808,700
917,700
1,340,600
Net Change In Cash
3,675,600
3,028,700
3,789,200
3,720,700
Free Cash Flow
967,600
773,600
995,800
1,107,600
Cash
1,995,800
3,090,200
2,488,200
2,011,800
Basic Shares
108,600
111,200
113,800
116,200

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$14,202,000
$13,117,200
$12,172,900
$16,071,700
Gross Profit
11,750,600
12,233,500
10,467,700
13,348,000
EBITDA
5,318,000
4,047,100
5,259,600
9,669,300
EBIT
4,835,100
4,047,100
4,918,200
9,383,100
Net Income
4,412,600
3,953,600
4,338,400
8,075,300
Net Change In Cash
14,202,000
13,117,200
12,172,900
16,071,700
Cost of Revenue
221,300
690,800
Free Cash Flow
3,664,600
3,667,600
4,424,800
6,529,400
Cash
2,488,200
2,730,000
3,105,900
2,885,600
Basic Shares
115,100
113,700
113,500
112,200

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
$12.89
2025-03-31
$8.22
2024-12-31
$12.07